Workflow
威高血净与泰尔茂中国拟对威高泰尔茂进行同比例增资
Shandong Weigao Blood Purification ProductsShandong Weigao Blood Purification Products(SH:603014) 智通财经网·2025-11-20 09:20

Core Viewpoint - Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business, in collaboration with Terumo China [1] Group 1: Capital Increase Details - The company plans to increase its investment by 72.5 million RMB [1] - After the capital increase, the registered capital of Weigao Terumo will rise from 160 million RMB to 305 million RMB [1] - The company's ownership stake in Weigao Terumo will remain unchanged at 50% [1] Group 2: Joint Venture Structure - Weigao Terumo will continue to be a jointly controlled entity between the company and Terumo China [1]